Perseus Proteomics Yönetim

Yönetim kriter kontrolleri 2/4

Perseus Proteomics CEO'su Takuya Yokokawa, Jun2018 tarihinde atandı, in görev süresi 6.42 yıldır. şirketin hisselerinin 0.41% doğrudan sahiptir ve bu hisselerin değeri ¥ 43.85M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.6 yıl ve 4 yıldır.

Anahtar bilgiler

Takuya Yokokawa

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	6.4yrs
CEO sahipliği	0.4%
Yönetim ortalama görev süresi	3.6yrs
Yönetim Kurulu ortalama görev süresi	4yrs

Son yönetim güncellemeleri

Recent updates

CEO

Takuya Yokokawa (64 yo)

6.4yrs

Görev süresi

Mr. Takuya Yokokawa has been President & Chief Executive Officer at Perseus Proteomics Inc since June 2018 and its Director since March 2018. Mr. Yokokawa serves as Executive Officer at Perseus Proteomics...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Takuya Yokokawa	President	6.4yrs	Veri yok	0.41% ¥ 43.8m
Tadashi Matsuura	CTO & Executive Officer	2.8yrs	Veri yok	Veri yok
Shinichi Suzukawa	Head of Administrative Dept	4.4yrs	Veri yok	0.16% ¥ 16.6m
Shinji Hagiwara	Executive Officer	2.4yrs	Veri yok	Veri yok

3.6yrs

Ortalama Görev Süresi

64.5yo

Ortalama Yaş

Deneyimli Yönetim: 4882 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Takuya Yokokawa	President	6.7yrs	Veri yok	0.41% ¥ 43.8m
Shinichi Suzukawa	Head of Administrative Dept	4.4yrs	Veri yok	0.16% ¥ 16.6m
Shinji Hagiwara	Executive Officer	1.4yrs	Veri yok	Veri yok
Nobuo Hanai	Independent Outside Director	3.7yrs	Veri yok	Veri yok
Tatsuhiko Kodama	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Hiroyuki Aburatani	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
Toshiya Tanaka	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Kinichiro Kominami	Independent Outside Director	6.4yrs	Veri yok	0.41% ¥ 43.4m
Tadashi Horiuchi	Independent Outside Director	4.4yrs	Veri yok	Veri yok
Takashi Ohno	Independent Outside Director	3.4yrs	Veri yok	Veri yok
Tatsuya Nagase	Independent Outside Director	2.4yrs	Veri yok	Veri yok

4.0yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 4882 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4 yıldır).

Perseus Proteomics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Perseus Proteomics Inc., Annual General Meeting, Jun 20, 2024

Perseus Proteomics Inc., Annual General Meeting, Jun 23, 2023

No independent directors

Perseus Proteomics Inc., Annual General Meeting, Jun 23, 2022

No independent directors

Recent updates

Perseus Proteomics Inc. Announces Registration of Patent Jointly Filed with Juntendo University

Perseus Proteomics Inc. to Report Q2, 2025 Results on Nov 14, 2024

First quarter 2025 earnings released: JP¥15.77 loss per share (vs JP¥35.89 loss in 1Q 2024)

Full year 2024 earnings released: JP¥93.65 loss per share (vs JP¥66.84 loss in FY 2023)

Full year 2024 earnings released: JP¥93.65 loss per share (vs JP¥66.84 loss in FY 2023)

Perseus Proteomics Inc., Annual General Meeting, Jun 20, 2024

Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera

New minor risk - Shareholder dilution

Perseus Proteomics Inc. announced that it has received ¥1.566 million in funding from Barclays Bank PLC (Tokyo Branch)

Perseus Proteomics Inc. to Report Fiscal Year 2024 Results on May 15, 2024

Third quarter 2024 earnings released

Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera

Perseus Proteomics Inc. to Report Q3, 2024 Results on Feb 14, 2024

Second quarter 2024 earnings released

Perseus Proteomics Inc. Announces Completion of Patients Enrollment in Phase I Clinical Trial for Polycythemia Vera (PV)

Perseus Proteomics Inc. Announces Sales Launch of New Antibodies/Reagents

Perseus Proteomics, Inc. Announces Provision of Antibody Research Support Service Through Single Cell Cloning Technology

Perseus Proteomics Inc. Announces on Dosing of the First Patient in Phase I/II Clinical Trial for Aggressive NK-Cell Leukemia

Perseus Proteomics Inc. to Report Q2, 2024 Results on Nov 13, 2023

First quarter 2024 earnings released: JP¥35.89 loss per share (vs JP¥17.01 loss in 1Q 2023)

Perseus Proteomics Inc. to Report Q1, 2024 Results on Aug 14, 2023

Perseus Proteomics Inc. Announces the Interim Report of Phase I Clinical Trial of PPMX-T003

Full year 2023 earnings released

Perseus Proteomics Inc., Annual General Meeting, Jun 23, 2023

Third quarter 2023 earnings released: JP¥16.92 loss per share (vs JP¥10.12 loss in 3Q 2022)

Perseus Proteomics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Perseus Proteomics Inc. Announces Extension of Phase I Clinical Trial of PPMX-T003 among Polycythemia Vera Patients

Perseus Proteomics Inc. to Report Q3, 2023 Results on Feb 13, 2023

Second quarter 2023 earnings released: JP¥13.86 loss per share (vs JP¥10.12 loss in 2Q 2022)

No independent directors

Second quarter 2023 earnings released: JP¥13.86 loss per share (vs JP¥10.12 loss in 2Q 2022)

Perseus Proteomics Inc. Provides Earnings Guidance for the Year Ending March 31, 2023

Perseus Proteomics Inc. to Report Q2, 2023 Results on Nov 11, 2022

Perseus Proteomics Inc. Announces First/Second Patients Dosed in Phase I Clinical Trial Among Polycythemia Vera (Pv) Patients

Perseus Proteomics Inc. Provides Earnings Guidance for the Year Ending March 31, 2023

Perseus Proteomics Inc. to Report Q1, 2023 Results on Aug 12, 2022

Perseus Proteomics Inc., Annual General Meeting, Jun 23, 2022

No independent directors

Perseus Proteomics Inc. to Report Fiscal Year 2022 Results on May 13, 2022

Perseus Proteomics Inc. Provides Earnings Guidance for the Year Ending March 31, 2022

Perseus Proteomics Inc. Announces Initiation of Phase I Clinical Trial in Polycythemia Vera Patients

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş